Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib resistance or intolerance accelerated-phase chronic myelogenous leukemia

1 Citations

Journal

  • Blood

    Blood 111 (4), 1834-1839, 2008

Citations (1)*help

See more

Details 詳細情報について

  • CRID
    1571135650845481856
  • NII Article ID
    10025162110
  • Data Source
    • CiNii Articles

Report a problem

Back to top